Cover Image
市場調查報告書

全球子宮頸癌疫苗的市場機會 (2020年)

Global Cervical Cancer Vaccine Market Opportunities, 2020

出版商 Pharmaion 商品編碼 346836
出版日期 內容資訊 英文 105 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球子宮頸癌疫苗的市場機會 (2020年) Global Cervical Cancer Vaccine Market Opportunities, 2020
出版日期: 2015年12月11日 內容資訊: 英文 105 Pages
簡介

子宮頸癌主要是透過性交感染人類乳突病毒 (HPV)而發病。HPV的病毒株中,HPV 16和HPV 18為子宮頸癌的發病因素。子宮頸癌疫苗,是針對癌症刺激、強化人體的免疫系的生物製藥。不論已開發國家、發展中國家,不當性交 (特別是青少年層) 增加,和人類乳突病毒(HPV)疫苗的接種率下降,9∼26歲的女性的子宮頸癌發病數量增加,促進子宮頸癌疫苗市場成長。全球子宮頸癌疫苗的市場規模,2020年預計達到16億美元。

本報告提供全球子宮頸癌疫苗的市場相關分析、市場整體規模與佔有率趨勢預測 (總計11年份) ,及各地區的詳細趨勢、法規與政策環境、主要企業簡介、市場結構的變化新的市場機會、對相關人員的建議內容等彙整,為您概述為以下內容。

第1章 產品概要

第2章 調查手法

第3章 分析師的見解

第4章 全球子宮頸癌患者的流行病學

第5章 全球子宮頸癌疫苗市場展望

  • 市場規模與其預測
    • 以金額為準
  • 市場佔有率與其預測
    • 各地區 (美國、EU各國、其他)
  • 各企業市場佔有率 (Merck & Co., Inc.、GlaxoSmithKline plc、Xiamen Innovax Biotech Co., Ltd.)

第6章 美國市場

  • 市場規模與其預測
    • 以金額為準
    • 以數量為準
  • 市場佔有率與其預測
    • 各企業 (Merck & Co., Inc.,GlaxoSmithKline plc)
  • 子宮頸癌患者的流行病學

第7章 歐洲市場展望

  • 市場規模與其預測
    • 以金額為準
    • 以數量為準
  • 市場佔有率與其預測
    • 各企業 (Sanofi Pasteur MSD、GlaxoSmithKline plc)
  • 子宮頸癌患者的流行病學

第8章 其他的國家 (RoW) 的市場展望

  • 市場規模與其預測
    • 以金額為準
  • 市場佔有率與其預測
    • 各企業 (GlaxoSmithKline plc、Merck Sharpe & Dome、Xiamen Innovax Biotech Co., Ltd.)

第9章 市場動態

  • 推動市場要素
  • 市場課題

第10章 市場趨勢與發展

  • 新產品的開發
  • 患者支援計劃
  • 人類乳突病毒 (HPV) 疫苗給藥數量低
  • 藥劑師參與的擴大

第11章 競爭環境

  • Merck & Co., Inc.
    • 企業概要
    • 法規概要:Gardasil
    • 臨床實驗概況:Gardasil
  • GlaxoSmithKline plc
    • 企業概要
    • 法規概要:Cervarix
    • 臨床實驗概況:Cervarix
  • Xiamen Innovax Biotech Co., Ltd.

第12章 策略性建議

圖表一覽

目錄

Cervical cancer is mainly caused by Human Papilloma Virus (HPV) infection transmitted via sexual contact with an HPV-infected person. Two strains of HPV that are responsible for causing cervical cancer are HPV 16 and HPV 18. Cervical cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Increasing rate of unprotected sex, especially among adolescents, across various developed as well as developing regions, is resulting in growing incidences of cervical cancer, globally. As a result, an increasing number of people, especially females in the age group of 9-26 years, are opting for cervical cancer vaccines. Moreover, reduction in the number of recommended doses of HPV immunisation from three to two, which enhances the uptake of vaccine among a large adolescent female population, is anticipated to drive the global cervical cancer market during 2015 - 2020.

According to Pharmaion report, “Global Cervical Cancer Vaccine Market Opportunities, 2020”, global cervical cancer vaccine market is anticipated to cross US$ 1.6 billion by 2020 on account of increasing immunization programs for HPV vaccination, rising prevalence of cervical cancer and favorable government initiatives to increase disease awareness. However, the unavailability of HPV vaccines in some regions of the world, uncertain reimbursement rates, and changes in regulatory guidelines are hindering the growth of this market. In 2014, the United States was the largest consumer of cervical cancer vaccines, and the country is expected to continue its dominance through 2020 owing to the launch of a nine-valent HPV vaccine, Gardasil 9, in 2014 which protects against the infection of all 9 types of HPV, as compared to Gardasil that protects against only four HPV types. Majorly, two US FDA approved HPV vaccines, namely, Gardasil (Merck & Co., Inc.) and Cervarix (GlaxoSmithKline plc), are available across the globe.

“Global Cervical Cancer Vaccine Market Opportunities, 2020” report elaborates following aspects related to global cervical cancer vaccine market:

  • Global Cervical Cancer Vaccine Market Size, Share & Forecast
  • Segmental Analysis - By Region & By Company
  • Policy & Regulatory Landscape
  • Changing Market Trends & Emerging Opportunities
  • Competitive Landscape & Strategic Recommendations

Why You Should Buy This Report?

  • To identify the on-going trends and anticipated growth in the next five years
  • To gain competitive knowledge of leading market players
  • To avail 10% customization in the report without any extra charges and get the research data or trends added in the report as per the buyer's specific needs

Table of Contents

1. Product Overview

2. Analyst View

3. Research Methodology

4. Global Cervical Cancer Patient Epidemiology

5. Global Cervical Cancer Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Region (United States, European Union & ROW)
  • 5.3. By Company (Merck & Co., Inc., GlaxoSmithKline plc & Xiamen Innovax Biotech Co., Ltd.)

6. United States Cervical Cancer Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
    • 6.1.2. By Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Company (Merck & Co., Inc. & GlaxoSmithKline plc)
  • 6.3. US Cervical Cancer Patient Epidemiology

7. Europe Cervical Cancer Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
    • 7.1.2. By Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Company (Sanofi Pasteur MSD & GlaxoSmithKline plc)
  • 7.3. Europe Cervical Cancer Patient Epidemiology

8. ROW Cervical Cancer Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Company (GlaxoSmithKline plc, Merck Sharpe & Dome and Xiamen Innovax Biotech Co., Ltd.)

9. Market Dynamics

  • 9.1. Drivers
  • 9.2. Challenges

10. Market Trends & Developments

  • 10.1. New Product Development
  • 10.2. Patient Assistance Program
  • 10.3. Reduced HPV Vaccine Dosage
  • 10.4. Expanding Involvement of Pharmacists

11. Competitive Landscape

  • 11.1. Merck & Co., Inc.
    • 11.1.1. Company Overview
    • 11.1.2. Regulatory Footprint: Gardasil
    • 11.1.3. Clinical Highlights: Gardasil
  • 11.2. GlaxoSmithKline plc
    • 11.2.1. Company Overview
    • 11.2.2. Regulatory Footprint: Cervarix
    • 11.2.3. Clinical Highlights: Cervarix
  • 11.3. Xiamen Innovax Biotech Co., Ltd.

12. Strategic Recommendations

List of Figures

  • Figure 1: Global Estimated Incidence and 5-Year Prevalence of Cancer of Cervix Uteri, By Number of Cases, 2012
  • Figure 2: Estimated Incidence of Cancer of Cervix Uteri, By Region, By Number of Cases, 2012
  • Figure 3: Global Cervical Cancer Vaccine Market Size, By Value, 2010-2020F (USD Million)
  • Figure 4: Global Cervical Cancer Vaccine Market Share, By Region, By Value, 2010-2020F
  • Figure 5: Global Cervical Cancer Vaccine Market Share, By Company, By Volume, 2010-2020F
  • Figure 6: United States Cervical Cancer Vaccine Market Size, By Value (USD Million), By Volume (‘000 Doses), 2010-2020F
  • Figure 7: United States Percentage of 13 to 17 Year-old Girls Completing HPV Vaccine 3 Dose, 2012
  • Figure 8: United States Percentage of 13 to 17 Year-old Girls Completing HPV Vaccine 3 Dose, 2014
  • Figure 9: United States Gardasil and Cervarix Vaccine for Children, Average Selling Price (ASP), 2010-2014, (USD/Dose)
  • Figure 10: United States Gardasil and Cervarix Vaccine for Adults Average Selling Price (ASP), 2010-2014, (USD/Dose)
  • Figure 11: United States Cervical Cancer Vaccine Market Share, By Company, By Value, 2010-2020F
  • Figure 12: United States High School Female Students Sexual Dating Violence, By Percentage, By Grade, 2013
  • Figure 13: United Sates Estimated Incidence of Cervix Uteri Cancer and Mortality, By Number of Cases, 2012, 2015E & 2020F
  • Figure 14: European Union Cervical Cancer Vaccine Market Size, By Value (USD Million), By Volume (‘000 Doses), 2010-2020F
  • Figure 15: Germany Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
  • Figure 16: Germany Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence
  • Figure 17: Italy Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
  • Figure 18: Italy Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence
  • Figure 19: France Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
  • Figure 20: France Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence & 5-year Prevalence
  • Figure 21: United Kingdom Cervix Uteri Cancer Incidence and Mortality, 2012, 2015E & 2020F
  • Figure 22: United Kingdom Cervix Uteri Cancer, 1-year Prevalence, 3-year Prevalence and 5-year Prevalence
  • Figure 23: European Union Cervical Cancer Vaccine Market Share, By Company, By Value, 2010-2020F
  • Figure 24: European Union Cervix Uteri Cancer Incidence and Mortality, By Number of Cases, 2012, 2015E & 2020F
  • Figure 25: Rest of the World Cervical Cancer Vaccine Market Size, By Value (USD Million), 2010-2020F
  • Figure 26: Japan Major Events Related to HPV Vaccines, 2010-2013
  • Figure 27: Japan Major Events Related to HPV Vaccines, 2013-2015
  • Figure 28: Australia HPV 3 Dose Vaccine Coverage for Females of Age 15 years, By State, By Number, 2014
  • Figure 29: Australia HPV 3-Dose Vaccine Coverage for Females of Age 15 years, By State, By Percentage, 2012-14
  • Figure 30: ROW Cervical Cancer Vaccine Market Share, By Region, By Value, 2010-2020F
  • Figure 31: Middle East and North Africa Estimated Incidence of Cancer of Cervix Uteri, By Number of Cases, 2012, 2015E & 2020F

List of Tables

  • Table 1: Process of Development of Cervical Cancer after an HPV Infection
  • Table 2: Global HPV Vaccines and their HPV Types
  • Table 3: European Union Recommended HPV Immunization, By Country, By Age
  • Table 4: Partial List of HPV Vaccination Practices across European Union
  • Table 5: Cervarix and Gardasil Prices offered by GAVI, By Dose, By Year
  • Table 6: Cervical Cancer Vaccine in Pipeline
  • Table 7: Europe Two-dose HPV Vaccines Schedule Marketing Authorization, By Year, By Age Group
  • Table 8: Countries with Regulatory Approval of Gardasil
  • Table 9: Key Results from Phase III Trials of Gardasil Vaccine
  • Table 10: Key Results from Phase III Trials of Cervarix Vaccine
Back to Top